Maternal and Neonatal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G Levels After the Pfizer-BioNTech Booster Dose for Coronavirus Disease 2019 (COVID-19) Vaccination During the Second Trimester of Pregnancy
Maternal and Neonatal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G Levels After the Pfizer-BioNTech Booster Dose for Coronavirus Disease 2019 (COVID-19) Vaccination During the Second Trimester of Pregnancy
复制标题
DOI：
10.1097/aog.0000000000004867
复制
发表时间：
2022-08-01
影响因子：
7.2
通讯作者：
Riskin-Mashiah, Shlomit
中科院分区：
文献类型：
--
作者：
Kugelman, Nir;Nahshon, Chen;Riskin-Mashiah, Shlomit
目的：评估孕中期接种辉瑞-生物科技信使核糖核酸(Pfizer-BioNTech Messenger RNA，Pfizer)冠状病毒病2019疫苗(Pfizer-BioNtech Messenger RNA，Pfizer)冠状病毒2019年疫苗(Pfizer-BioNTech Messenger Rna，新冠肺炎)后，孕妇和新生儿出生时的SARS-CoV-2免疫球蛋白抗体水平，并与孕中期接种两剂疫苗的孕妇进行比较。方法：我们进行了一项前瞻性队列研究，研究对象为在怀孕17-30周接受第三剂辉瑞新冠肺炎疫苗接种的孕妇(强化组)，以及既往没有SARS-CoV-2感染史的孕妇。孕妇和新生儿的抗体水平在分娩入院时和出生后脐带血中进行了测量。加强组的抗体水平与在相同孕周窗口内接种第二剂疫苗(两剂组)的历史对照组孕妇的抗体水平进行了比较。结果：2021年10月至2022年2月，121名妇女和109名新生儿在加强免疫后平均+/-SD为15.3+/-3.9周检测到抗体水平。新生儿的滴度比母亲的滴度高两倍，母亲和新生儿出生时的滴度与第三次接种疫苗的时间间隔呈负相关。两剂组包括121名妇女和107名新生儿，第二剂后抗体水平的平均+/-SD为14.6+/-2.6周。加强免疫组母体抗体中位数滴度(4,485[2,569-9,702]AU/m L)高于两剂组(1,122[735-1,872]AU/m L)(P
OBJECTIVE: To evaluate maternal and neonatal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) antibody levels at birth after a third (booster) dose of the Pfizer-BioNTech messenger RNA (Pfizer) coronavirus disease 2019 (COVID-19) vaccine during the second trimester of pregnancy, and compare them with those in women who received two vaccine doses during the second trimester. METHODS: We conducted a prospective cohort study of women admitted to the delivery ward at a single center who received the third Pfizer COVID-19 vaccine dose (booster group) at 17-30 weeks of pregnancy and who did not have previous SARS-CoV-2 infection. Maternal and neonatal antibody levels were measured on admission for delivery and in the umbilical cord blood after birth. Antibody levels for the booster group were compared with those in a historical control group of pregnant women who received their second vaccine dose (two-dose group) within the same gestational age window. RESULTS: Between October 2021 and February 2022, antibody levels were measured in 121 women and 109 neonates at a mean +/- SD of 15.3 +/- 3.9 weeks after booster vaccination. Neonatal titers measured two times higher than maternal titers, with inverse correlation between maternal and neonatal titers at birth and time interval from third vaccination. The two-dose group included 121 women and 107 neonates, with antibody levels measured at a mean +/- SD of 14.6 +/- 2.6 weeks after the second dose. Median [interquartile range] maternal antibody titers were higher in the booster group (4,485 [2,569-9,702] AU/mL) compared with the two-dose group (1,122 [735-1,872] AU/mL) (P